Thomas Gad - 17 Jan 2023 Form 4 Insider Report for Y-mAbs Therapeutics, Inc. (YMAB)

Role
Founder, President, Interim Chief Executive Officer and Head of Business Development & Strategy, Director
Signature
/s/ Thomas Gad
Issuer symbol
YMAB
Transactions as of
17 Jan 2023
Net transactions value
$0
Form type
4
Filing time
19 Jan 2023, 15:42:34 UTC
Previous filing
19 May 2022
Next filing
08 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction YMAB Common Stock Award $0 +40,500 +81% $0.000000 90,500 17 Jan 2023 Direct F1
holding YMAB Common Stock 565,032 17 Jan 2023 By GAD Enterprises LLC F2
holding YMAB Common Stock 60,000 17 Jan 2023 By Children F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction YMAB Employee Stock Option (right to buy) Award $0 +243,200 $0.000000 243,200 17 Jan 2023 Common Stock 243,200 $4.70 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents 40,500 restricted stock units ("RSUs") granted to the Reporting Person pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. Each RSU represents a contingent right to receive one share of Common Stock on the vesting dates of the RSU. The RSUs vest by 1/3 on each of January 17, 2024, January 17, 2025 and January 17, 2026 subject to the continuing employment of the Reporting Person on each vesting date.
F2 Reporting Person is sole member of GAD Enterprises, LLC and the sole member and manager of GAD Management, LLC, the manager of GAD Enterprises, LLC, and as such Reporting Person has sole voting and dispositive power with respect to such shares.
F3 Represents shares owned by Reporting Person's children who are deemed to share Reporting Person's household.
F4 Stock options granted to the Reporting Person pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc.
F5 The stock options shall vest and become exercisable as to 25% of the shares subject to the option on January 17, 2024, and thereafter vests and become exercisable as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

Remarks:

Founder, President, Interim Chief Executive Officer and Head of Business Development & Strategy